Up-Regulation of Drug Resistance-Related Vaults During Dendritic Cell Development1

P-glycoprotein (Pgp) and vaults are associated with multidrug resistance in tumor cells, but their physiological functions are not yet clear. Pgp, the prototypical transmembrane transporter molecule, may also facilitate the migration of skin dendritic cells (DC). Vaults—ribonucleoprotein cell organelles, frequently overexpressed in Pgp-negative drug-resistant tumor cells—have also been associated with intracellular transport processes. Given the pivotal role of DC in dealing with exposure to potentially harmful substances, the present study was set out to examine the expression of Pgp and vaults during differentiation and maturation of DC. DC were obtained from different sources, including blood-derived monocytes, CD34+ mononuclear cells, and chronic myeloid leukemia cells. Whereas flow cytometric and immunocytochemical analyses showed slightly augmented levels of Pgp, up-regulation of vault expression during DC culturing was strong, readily confirmed by Western blotting, and independent of the source of DC. In further exploring the functional significance of vault expression, it was found that supplementing DC cultures with polyclonal or mAbs against the major vault protein led to lower viabilities of LPS- or TNF-α-matured monocytes-DC. Moreover, expression of critical differentiation, maturation, and costimulatory molecules, including CD1a and CD83, was reduced and their capacity to induce Ag-specific T cell proliferative and IFN-γ release responses was impaired. These data point to a role for vaults in both DC survival and functioning as APC.

[1]  E. Wiemer,et al.  Detection of the Mr 110,000 Lung Resistance-related Protein LRP/MVP with Monoclonal Antibodies , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[2]  O. Fardel,et al.  Differential expression of the efflux pumps P-glycoprotein and multidrug resistance-associated protein in human monocyte-derived dendritic cells. , 2001, Human immunology.

[3]  G. Woods,et al.  Evidence that natural killer cells express mini P‐glycoproteins but not classic 170 kDa P‐glycoprotein , 2001, British journal of haematology.

[4]  A. Osterhaus,et al.  A randomized, double blind study in young healthy adults comparing cell mediated and humoral immune responses induced by influenza ISCOM vaccines and conventional vaccines. , 2000, Vaccine.

[5]  D. Jäger,et al.  The Leukotriene C4 Transporter MRP1 Regulates CCL19 (MIP-3β, ELC)–Dependent Mobilization of Dendritic Cells to Lymph Nodes , 2000, Cell.

[6]  V. Kickhoefer,et al.  The Mr 193,000 vault protein is up-regulated in multidrug-resistant cancer cell lines. , 2000, Cancer research.

[7]  C Caux,et al.  Immunobiology of dendritic cells. , 2000, Annual review of immunology.

[8]  A. Harris,et al.  Human cultured dendritic cells show differential sensitivity to chemotherapy agents as assessed by the MTS assay , 1999, British Journal of Cancer.

[9]  S. Takao,et al.  Multidrug resistance and the lung resistance-related protein in human colon carcinoma SW-620 cells. , 1999, Journal of the National Cancer Institute.

[10]  P. Stewart,et al.  Structure of the vault, a ubiquitous celular component. , 1999, Structure.

[11]  L. Rome,et al.  Recombinant Major Vault Protein Is Targeted to Neuritic Tips of PC12 Cells , 1999, The Journal of cell biology.

[12]  G. Piluso,et al.  Interaction of Vault Particles with Estrogen Receptor in the MCF-7 Breast Cancer Cell , 1998, The Journal of cell biology.

[13]  R. Steinman,et al.  A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vessels. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  V. Kickhoefer,et al.  Vaults Are Up-regulated in Multidrug-resistant Cancer Cell Lines* , 1998, The Journal of Biological Chemistry.

[15]  G. Donelli,et al.  Intracellular expression of P-170 glycoprotein in peripheral blood mononuclear cell subsets from healthy donors and HIV-infected patients. , 1998, Haematologica.

[16]  T. Tsuruo,et al.  P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[17]  D. Hart,et al.  Dendritic cells: unique leukocyte populations which control the primary immune response. , 1997, Blood.

[18]  K. Suprenant,et al.  Characterization of the sea urchin major vault protein: a possible role for vault ribonucleoprotein particles in nucleocytoplasmic transport. , 1997, Developmental biology.

[19]  K. Kliche,et al.  Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia. , 1997, Blood.

[20]  R. Kellner,et al.  The Major Vault Protein (MVP100) Is Contained in Cholinergic Nerve Terminals of Electric Ray Electric Organ* , 1996, The Journal of Biological Chemistry.

[21]  U. Germann,et al.  P-glycoprotein--a mediator of multidrug resistance in tumour cells. , 1996, European journal of cancer.

[22]  L. Rome,et al.  Dictyostelium Vaults: Disruption of the Major Proteins Reveals Growth and Morphological Defects and Uncovers a New Associated Protein (*) , 1995, The Journal of Biological Chemistry.

[23]  H. Clevers,et al.  The drug resistance-related protein LRP is the human major vault protein , 1995, Nature Medicine.

[24]  L. Pilarski,et al.  Intrinsic expression of the multidrug transporter, P-glycoprotein 170, in multiple myeloma: implications for treatment. , 1995, Leukemia & lymphoma.

[25]  M. Willingham,et al.  P‐glycoprotein epitope mapping. I. Identification of a linear human‐specific epitope in the fourth loop of the P‐glycoprotein extracellular domain by MM4.17 murine monoclonal antibody to human multi‐drug‐resistant cells , 2007, International journal of cancer.

[26]  A. Molinari,et al.  P‐glycoprotein expression in the Golgi apparatus of multidrug‐resistant cells , 1994, International journal of cancer.

[27]  N. Kedersha,et al.  Evidence that vault ribonucleoprotein particles localize to the nuclear pore complex. , 1993, Journal of cell science.

[28]  M. Slovak,et al.  Overexpression of a M(r) 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. , 1993, Cancer research.

[29]  F. Baas,et al.  Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. , 1993, Cancer research.

[30]  I. Roninson,et al.  Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[31]  D. Chugani,et al.  Unlocking vaults: organelles in search of a function. , 1991, Trends in cell biology.

[32]  L. Rome,et al.  Vaults. II. Ribonucleoprotein structures are highly conserved among higher and lower eukaryotes , 1990, The Journal of cell biology.

[33]  J. Gariépy,et al.  Detection of P-glycoprotein isoforms by gene-specific monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[34]  J. Bulte,et al.  Monoclonal antibody JSB‐1 detects a highly conserved epitope on the P‐glycoprotein associated with multi‐drug‐resistance , 1988, International journal of cancer.

[35]  N. Mulder,et al.  Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. , 1987, Cancer research.

[36]  T. Tsuruo,et al.  Functional role for the 170- to 180-kDa glycoprotein specific to drug-resistant tumor cells as revealed by monoclonal antibodies. , 1986, Proceedings of the National Academy of Sciences of the United States of America.